Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anastrozole + gefitinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of anastrozole, an aromatase inhibitor that blocks estrogen production, and gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination aims to simultaneously target estrogen receptor and EGFR signaling pathways, which are implicated in cancer progression and treatment resistance.
02
Targets
EGFR (Epidermal growth factor receptor)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on anastrozole + gefitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anastrozole + gefitinib.